Statistical considerations for the efficacy assessment of clinical studies of vulvar and vaginal atrophy

Drug Information Journal

Volumn 44, Issue 5, 2010, Pages 581-588

  Chen, Ling ^a   Ng, Moh Jee ^a   Van Der Vlugt, Theresa H ^a   Price, Phill H ^a   Orencia, Anthony ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Atrophic vaginitis; Coprimary endpoints; Efficacy assessment; Menopause; Vulvar and vaginal atrophy indication

Indexed keywords

GESTAGEN; PLACEBO;

CELL; CELL MATURATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DISEASE SEVERITY; DYSPAREUNIA; DYSURIA; FEMALE; HORMONAL THERAPY; HUMAN; PH; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CELL; VAGINA PH; VAGINAL DRYNESS; VAGINAL PRURITUS; VULVA ATROPHY; VULVA DISEASE;

EID: 78650182297     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400505     Document Type: Review

References (9)

1. US Food and Drug Administration. Draft guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation. 2003. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338. pdf.
2. International Conference on Harmonization. Guidance: E9 statistical principles for clinical trials. Fed Regist. 1998;63(179):49483-49498.
3. Offen W, Chuang-Stein C, Dmitrienko A, et al. Multiple co-primary endpoints: medical and statistical solutions - a report from the multiple endpoints expert team of the Pharmaceutical Research and Manufacturers of America. Drug Inf J. 2007;41(1):31-46.
4. Huque MF, Chen L, Sobhan M. Type I error rate and sample size issues for confirmatory trials with co-primary endpoints. Paper presented at the 2nd FDA/DIA Statistics Forum, Washington, DC, 2008.
5. Chen L, Ng MJ, van der Vlugt TH, Price P, Orencia A. Statistical considerations on multiple co-primary endpoints in vulvar and vaginal atrophy clinical studies. Paper presented at the 6th International Conference on Multiple Comparison Procedures, Tokyo, Japan, 2009.
6. Chen L. Statistical issues with multiple co-primary endpoints in vulvar and vaginal atrophy clinical studies. Paper presented at 2008 ICSA Applied Statistics Symposium, Piscataway, New Jersey.
7. Huque MF. Statistical testing for multiple co-primary endpoints in clinical trials: type I error rate concepts and sample size issues. Paper presented at 2008 ICSA Applied Statistics Symposium, Piscataway, New Jersey.
8. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials. 2000;21:527-539.
9. Castelo-Branco C, Cancelo M, Villero J, Nohales F. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52:46-52.